• No results found

[PDF] Top 20 Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy

Has 10000 "Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy" found on our website. Below are the top 20 most common "Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy".

Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy

Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy

... Japan). Acute ICSCR was diagnosed if patients had: subretinal fluid involving the macula associated with idiopathic leaks from the retinal pigment epithelium seen on fluorescein angiography; ... See full document

7

Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy

Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy

... The subfoveal choroidal thickness was measured as the distance between the outer border of the RPE-Bruch’s membrane complex and the chorioscleral border under the ...measured serous retinal ... See full document

5

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy

... 2011. Patients with symptomatic acute CSC, undergoing PDT using a half-dose of verteporfin (Visudyne; Novartis AG, Bülach, Switzerland) were ...The patients underwent fundus examinations and had ... See full document

6

The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: a retrospective case–control study

The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: a retrospective case–control study

... Central serous chorioretinopathy was a usually self- limited condition which in general spontaneously resolves within 4–6 months; therefore observation was preferred over treatment in the first ... See full document

8

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy

... on choroidal thick- ness, as can be done by enhanced depth imaging ...oidal thickness is significantly altered by half-dose PDT and whether this correlates with treatment ...assess patients at 1 year ... See full document

6

Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy

Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy

... eight patients achieved complete resolution in subretinal fluid following combination ...combination therapy was 7.5 months. Mean central macular thickness on OCT decreased significantly from ... See full document

6

Efficacy of 1/3 Dose Verteporfin Photodynamic Therapy for Subacute Central Serous Chorioretinopathy

Efficacy of 1/3 Dose Verteporfin Photodynamic Therapy for Subacute Central Serous Chorioretinopathy

... The central foveal thickness (CFT), neuroretinal thickness (NRT), height of subfoveal retinal fluid (SRF), and subfoveal choroidal thick- ness (SCT) were observed at baseline and ... See full document

9

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration

... However, patients treated with anti- VEGF agent often receive intravitreal injections on regular 4–6 weeks interval with increasing potential risk of ocular complications (Rosenfi eld et al 2005; Avery et al ... See full document

8

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy

... Japanese patients with treatment-naïve PCV were prospectively ...mean central retinal thickness (CRT) at 3, 6, 9, 12, 18, and 24 months after initial ... See full document

6

The effect of eradicating <em>Helicobacter pylori</em> on idiopathic central serous chorioretinopathy patients

The effect of eradicating <em>Helicobacter pylori</em> on idiopathic central serous chorioretinopathy patients

... ICSCR could have spontaneous resolution and a good visual prognosis; however, nearly half of cases tend to relapse, and this always in the same eyes. A small percentage of subjects could develop a chronic disease with ... See full document

6

Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions

Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions

... the patients, but did not prevent deterioration of BCVA in some ...of patients is needed to improve the technique of Ironing PDT and confirm the effect for long periods of ...in patients with AMD ... See full document

6

In patients suffering from idiopathic central serous chorioretinopathy, anxiety scores are higher than in healthy controls, but do not vary according to sex or repeated central serous chorioretinopathy

In patients suffering from idiopathic central serous chorioretinopathy, anxiety scores are higher than in healthy controls, but do not vary according to sex or repeated central serous chorioretinopathy

... all patients suffering from CSCR for a second time, no residual or irreversible impairments of the ocular apparatus have been observed or reported in the ophthalmologic ...had patients not learned from ... See full document

6

Multiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy

Multiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy

... Figure 1 (A) Fluorescein angiography (FA) showing multiple areas of retinal pigment epithelium decompensation. The lines (B–D) correspond to the optical coherence tomography (OCT) scans with the same letter. OCT revealed ... See full document

6

Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report

Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report

... focal choroidal excavation (FCE) – was discovered by Jampol in 2006 [1], its nature has been a ...to chorioretinopathy over an observation period ...in central serous chorioretinopathy ... See full document

6

Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up

Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up

... weeks after the initial treatment. The patients were given detailed information about the natural course of the disease and about the results of alternative therapeutic and surgical approaches for IPCV ... See full document

5

Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]

Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]

... All patients received a thorough expla- nation of the study design and aims, and were provided with written informed ...consent. Patients were seen at Aso- ciación Para Evitar la Ceguera en Mexico, ...All ... See full document

7

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone

... lines after 12 months follow-up (Chan et al ...treated patients (Nicolo et al ...re-treatment after combined therapy with PDT and 4 mg TA, ... See full document

6

Recent developments in age-related macular degeneration: a review

Recent developments in age-related macular degeneration: a review

... Various classification systems are used to delineate and characterize AMD for both clinical and research purposes. Currently, there is no universally accepted consensus on specific definitions, although conventionally, ... See full document

18

The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy

The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy

... ONL thickness increased by about 11 μm in some resolved CSC eyes compared with that in their active phase, which is con- sistent with our findings ...ONL thickness remains unclear, the following scenario is ... See full document

6

Choroidal thickness in older patients with central serous chorioretinopathy

Choroidal thickness in older patients with central serous chorioretinopathy

... The measurement of the choroid was not possible in 5 eyes (29.4 %) with active CSCR and in two inactive con- tralateral eyes (15.4 %). This is likely due to a loss of signal penetration and intensity due to the increased ... See full document

6

Show all 10000 documents...